Phreesia, Inc. $PHR Shares Purchased by Greenhouse Funds LLLP

Key Points

• Greenhouse Funds LLLP increased its stake in Phreesia, Inc. by 2.9% during the 1st quarter, now holding approximately 5.03% of the company worth $75.6 million.
• Insider selling has been notable, with Director Lisa Egbuonu-Davis selling 2,802 shares and Mark Douglas Smith selling 7,000 shares, contributing to a total of 119,874 shares sold by insiders in the last 90 days.
• Despite some insider sales, Phreesia has received positive analyst ratings, with upgrades from firms like Truist and KeyCorp, reflecting investor optimism about the company's performance.

Greenhouse Funds LLLP boosted its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 2.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,956,910 shares of the company's stock after purchasing an additional 83,018 shares during the quarter. Phreesia comprises about 3.5% of Greenhouse Funds LLLP's holdings, making the stock its 13th largest position. Greenhouse Funds LLLP owned 5.03% of Phreesia worth $75,579,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV acquired a new position in Phreesia in the 1st quarter valued at about $74,000. CWM LLC increased its stake in shares of Phreesia by 994.9% during the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after acquiring an additional 3,671 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Phreesia by 53.0% during the 1st quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock valued at $137,000 after acquiring an additional 1,825 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Phreesia by 1,023.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock valued at $142,000 after acquiring an additional 5,156 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Phreesia by 10,605.7% during the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after acquiring an additional 5,621 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Insider Activity at Phreesia

In other news, Director Lisa Egbuonu-Davis sold 2,802 shares of the stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $27.67, for a total transaction of $77,531.34. Following the completion of the transaction, the director directly owned 22,037 shares in the company, valued at approximately $609,763.79. This represents a 11.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark Douglas Smith sold 7,000 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $29.00, for a total value of $203,000.00. Following the transaction, the director owned 37,353 shares of the company's stock, valued at approximately $1,083,237. This trade represents a 15.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,874 shares of company stock worth $3,587,618. 5.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Truist Financial upped their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, May 29th. Citigroup reissued a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Mizuho began coverage on shares of Phreesia in a research report on Wednesday, August 27th. They set an "outperform" rating and a $36.00 target price for the company. KeyCorp increased their target price on shares of Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. Finally, Canaccord Genuity Group decreased their price target on Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th. One research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Phreesia has an average rating of "Buy" and an average price target of $32.54.

Phreesia Stock Performance

Phreesia stock opened at $30.40 on Thursday. The stock has a market cap of $1.81 billion, a P/E ratio of -41.09 and a beta of 0.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $28.28 and a 200-day moving average of $26.55. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $32.76.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.